Psychiatr. praxi. 2021;22(2):99-104 | DOI: 10.36290/psy.2021.020

Josephine: a case report of a polymorbid patient with ADHD

MUDr. Hedvika Ernsten
Psychiatrické oddělení Oblastní nemocnice Jičín

ADHD symptoms in adulthood may not be the patient's only problem; it may be overshadowed by other clinically significant serious psychiatric syndromes. Differential diagnosis of episodes of affective disorder accompanied by a later detected psychotic illness and differentiation of the primarily based core ADHD symptoms is quite possible provided that a detailed data of patient's clinical history are obtained. In the pharmacotherapy of such a patient it is useful to set individual therapeutic priorities which are not always the same for each and everyone. Treatment can be similarly complicated as polymorbidity, where monotherapy is seldom sufficient. It is also necessary to take the occurrence of adverse events into account including the less frequent ones, such as high sensitivity to the undesired effects of medication occuring even at usual therapeutical doses.

Keywords: ADHD, comorbid disease, bipolar affective disorder, psychotic disorder, cognitive deficit, differential diagnosis, lithiotherapy, lithium toxicity, thymostabilizers, metabolic effects of antipsychotics.

Published: July 9, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ernsten H. Josephine: a case report of a polymorbid patient with ADHD. Psychiatr. praxi. 2021;22(2):99-104. doi: 10.36290/psy.2021.020.
Download citation

References

  1. Mohr P, Anders M, Přikryl R, Masopust J, Praško J, Hoschl C. Konsensus ČNPS o diagnostice a léčbě ADHD v dospělosti. Psychiatrie. Praha: Tigis, 2013; 17(4): 189-202. ISSN 1211-7579.
  2. Kooij SJ, Bejerot S, Blackwell A, et al. European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD. BMC Psychiatry 2010; 10: 67. Published 2010 Sep 3. doi:10.1186/1471-244X-10-67 Go to original source... Go to PubMed...
  3. Hamshere ML, Stergiakouli E, Langley K, et al. Shared polygenic contribution between childhood attention-deficit hyperactivity disorder and adult schizophrenia. Br J Psychiatry 2013; 203(2): 107-111. doi:10.1192/bjp.bp.112.117432 Go to original source... Go to PubMed...
  4. Levy E, Traicu A, Iyer S, Malla A, Joober R. Psychotic disorders comorbid with attention-deficit hyperactivity disorder: an important knowledge gap. Can J Psychiatry. 2015; 60(3 Suppl 2): S48-52. PMID: 25886680; PMCID: PMC4418622. Go to PubMed...
  5. Vitiello B, Perez Algorta G, Arnold LE, Howard AL, Stehli A, Molina BS. Psychotic Symptoms in Attention-Deficit/Hyperactivity Disorder: An Analysis of the MTA Database. J Am Acad Child Adolesc Psychiatry 2017; 56(4): 336-343. doi:10.1016/j.jaac.2017.01.016. Go to original source... Go to PubMed...
  6. Katzman MA, Bilkey TS, Chokka PR, Fallu A, Klassen LJ. Adult ADHD and comorbid disorders: clinical implications of a dimensional approach. BMC Psychiatry. 2017; 17(1): 302. Published 2017 Aug 22. doi:10.1186/s12888-017-1463-3. Go to original source... Go to PubMed...
  7. Corbisiero S, Riecher-Rössler A, Buchli-Kammermann J, Stieglitz RD. Symptom Overlap and Screening for Symptoms of Attention-Deficit/Hyperactivity Disorder and Psychosis Risk in Help-Seeking Psychiatric Patients. Front Psychiatry 2017; 8: 206. Published 2017 Oct 30. doi:10.3389/fpsyt.2017.00206 Go to original source... Go to PubMed...
  8. Viktorin A, Rydén E, Thase ME, Chang Z, Lundholm C, D'Onofrio BM, Almqvist C, Magnusson PK, Lichtenstein P, Larsson H, Landén M. The Risk of Treatment-Emergent Mania With Methylphenidate in Bipolar Disorder. Am J Psychiatry. 2017; 174(4): 341-348. doi: 10.1176/appi.ajp.2016.16040467. Epub 2016 Oct 3. Erratum in: Am J Psychiatry. 2016; 173(11): 1154. PMID: 27690517; PMCID: PMC6641557. Go to original source... Go to PubMed...
  9. Wolke SA, Mehta MA, O'Daly O, et al. Modulation of anterior cingulate cortex reward and penalty signalling in medication-naive young-adult subjects with depressive symptoms following acute dose lurasidone. Psychol Med. 2019; 49(8): 1365-1377. doi:10.1017/S0033291718003306. Go to original source... Go to PubMed...
  10. Masopust J. Kardiometabolické riziko u nemocných schizofrenií, Psychiatrie. 2020; 3: 138-144.
  11. Mohr P, Masopust J. Lurasidon: profil antipsychotika druhé generace, Psychiatrie 2019; 4: 197-204.
  12. Loebel A, Cucchiaro J, Silva R, Kroger H, Sarma K, Xu J, Calabrese JR. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014; 171(2): 169-177. doi: 10.1176/appi.ajp.2013.13070985. Go to original source... Go to PubMed...
  13. Loebel A, Citrome L. Lurasidone: a novel antipsychotic agent for the treatment of schizophrenia and bipolar depression. BJPsych Bull. 2015;39(5):237-241. doi:10.1192/pb.bp.114.048793. Go to original source... Go to PubMed...
  14. Calabrese JR, Pikalov A, Streicher C, Cucchiaro J, Mao Y, Loebel A. Lurasidone in combination with lithium or valproate for the maintenance treatment of bipolar I disorder. Eur Neuropsychopharmacol. 2017; 27(9): 865-876. doi: 10.1016/j.euroneuro.2017.06.013. Epub 2017 Jul 6. PMID: 28689688. Go to original source... Go to PubMed...
  15. Nikiforuk A. Targeting the Serotonin 5-HT7 Receptor in the Search for Treatments for CNS Disorders: Rationale and Progress to Date. CNS Drugs. 2015; 29(4): 265-275. doi: 10.1007/s40263-015-0236-0. PMID: 25721336; PMCID: PMC4555343. Go to original source... Go to PubMed...
  16. Yanofski J. The dopamine dilemma: using stimulants and antipsychotics concurrently. Psychiatry (Edgmont). 2010; 7(6): 18-23.in Neuro-psychopharmacology & Biological Psychiatry 2013; 40: 221-228, DOI: 10.1016/j.pnpbp.2012.08.012,Published online 2017 Oct 2. Go to original source...
  17. Foulser P, Abbasi Y, Mathilakath A, Nilforooshan R. Do not treat the numbers: lithium toxicity. BMJ Case Rep. 2017; 2017: bcr2017220079. Published 2017 Jun 2. doi:10.1136/bcr-2017-220079 Go to original source... Go to PubMed...
  18. Qaswal AB. Lithium Stabilizes the Mood of Bipolar Patients by Depolarizing the Neuronal Membrane Via Quantum Tunneling through the Sodium Channels. Clin Psychopharmacol Neurosci. 2020; 18(2): 214-218. doi:10.9758/cpn.2020.18.2.214. Go to original source... Go to PubMed...
  19. Won E, Kim YK. An Oldie but Goodie: Lithium in the Treatment of Bipolar Disorder through Neuroprotective and Neurotrophic Mechanisms. Int J Mol Sci. 2017; 18(12): 2679. Published 2017 Dec 11. doi:10.3390/ijms18122679. Go to original source... Go to PubMed...
  20. Kumar, Rajeeva; Sachdev, Perminder Sb Akathisia and second-generation antipsychotic drugs, Current Opinion in Psychiatry 2009; 22(3): 293-299 doi: 10.1097/YCO.0b013e32832a16da. Go to original source... Go to PubMed...
  21. Musco S, McAllister V, Caudle I. Dopamine-receptor blocking agent-associated akathisia: a summary of current understanding and proposal for a rational approach to treatment. Ther Adv Psychopharmacol. 2020; 10: 2045125320937575. Published 2020 Aug 27. doi:10.1177/2045125320937575. Go to original source... Go to PubMed...




Psychiatry for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.